-
Media ReleaseNovartis Pharmaceuticals Corporation embarks on Alzheimer’s disease educational effort for the U.S. Hispanic community
-
Media ReleaseFDA Advisory Committee supports use of tobramycin inhalation powder from Novartis for patients with cystic fibrosis
-
Media ReleaseHigher dose of Novartis drug Exelon® Patch approved by FDA for patients with mild to moderate Alzheimer's disease
-
Media ReleaseNovartis Phase III study shows RLX030 improved symptoms and reduced deaths by one-third in patients with acute heart failure
-
Media ReleaseLeeza Gibbons joins Novartis to improve caregiving experience for millions of Americans through real-world peer advice on AlzheimersDisease.com
-
Media ReleaseNovartis Pharmaceuticals Corporation emprende una campaña de educación de la comunidad hispana de EE. UU. sobre la enfermedad de Alzheimer
-
Media ReleaseNEJM published study shows Novartis compound ACZ885 significantly relieves symptoms in patients with serious form of childhood arthritis
-
Media ReleaseMultimedia Assets: Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
-
Media ReleaseNovartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
-
Media ReleaseNovartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
-
Media ReleaseNovartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients
-
Media ReleaseNovartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia